Tag: FDA exclusivity

Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market

Biologic drugs in the U.S. enjoy 12 years of exclusivity before biosimilars can enter, delaying affordable alternatives. Learn how patent laws, complex development, and litigation block competition-and who pays the price.

Read More